Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
Phase 3
- Conditions
- Small-cell Lung Cancer
- Interventions
- Drug: Palcebo; Carboplatin; Etoposide；RadiotherapyDrug: SHR-1316; Carboplatin; Etoposide；Radiotherapy
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 486
- Registration Number
- NCT04691063
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- Drug: Fuzuloparib Placebo， Abiraterone acetate and PrednisoneDrug: Fuzuloparib , Abiraterone acetate and Prednisone
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 496
- Registration Number
- NCT04691804
- Locations
- 🇨🇳
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
🇨🇳The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
🇨🇳Northern Jiangsu People's Hospital, YangZhou, China
Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04688008
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Phase 2
Active, not recruiting
- Conditions
- Recurrent or Metastatic Cervical Cancer
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT04680988
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
Phase 1
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pyrotinib
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04680091
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT04679038
- Locations
- 🇨🇳
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
Phase 1
Completed
- Conditions
- Prostate Cancer Patients
- Interventions
- Drug: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04676035
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04667156
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
Phase 3
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Drug: Retagliptin, Henagliflozein, metformin XR
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 760
- Registration Number
- NCT04667143
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
Phase 1
- Conditions
- Prostate Cancer Patients
- Interventions
- Drug: Repaglinide, Bupropion and SHR3680
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04664725
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath